Filing Flows › Health Care › GeoVax Labs (GOVX)
GeoVax Labs (GOVX) earnings and revenue breakdown
Latest: Q2 2025 · 10-Q filed Jul 28, 2025 · GeoVax Labs (GOVX) Q2 2025 earnings results →
Q2 2025 Revenue up 184% year over year to $852K · 630¢ of every $1 of revenue lost · operating margin -635.8%
GeoVax Labs made $852K in Q2 2025 (+184% Y/Y). Operating margin -635.8%, net loss $5.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Jul 28, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $852K in Q2 2025, up 183% year over year and down 48% from the previous quarter.
Operating costs exceeded revenue by $5.4M, an operating margin of -635.8%. Total costs grew 17% against revenue growth of 183%. The fastest-growing cost line was General & admin (+42%). The quarter ended with a net loss of $5.4M, wider than the previous quarter's $5.4M loss.
Operating cash flow was −$4.3M. Non-cash charges added back $17K of depreciation and amortization and $293K of share-based compensation. Working capital and other items added $726K. Capital expenditures of $11K exceeded it, leaving free cash flow of −$4.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2025 | 10-Q | Jul 28, 2025 | $852K | +184% | -635.8% | −$5.4M | −$4.3M |
| Q1 2025 | 10-Q | May 1, 2025 | $1.6M | — | -330.2% | −$5.4M | −$6.0M |
| Q4 2024 | 10-K | Mar 27, 2025 | $864K | — | -965.3% | −$8.3M | −$7.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About GeoVax Labs
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity.
In its own words, from its 8-K, filed Jul 27, 2026.
GeoVax Labs against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +184% against the peers' median +10%. Operating margin: -635.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GOVX GeoVax Labs | Q2 2025 | $852K | +184% | -635.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: GeoVax Labs 10-Q on SEC EDGAR · CIK 832489 · Pharmaceutical Preparations
13F: who owns GOVX and who is buying
More on GOVX
History
Every quarter: Q2 2025 results · Q1 2025 results · Q4 2024 results